文献速递临床试验与 GCP基础与转化研究

评估透皮维生素D磷酸酯补充剂(TransVitD)安全性和有效性的多阶段双盲安慰剂对照研究

A multistage double-blind placebo-controlled study to assess the safety and efficacy of transdermal vitamin D phosphate supplementation (TransVitD).
PubMed 文献 · Trials · 2025-02-19

本研究为单中心、12周、分两部分的临床试验,最多纳入100名参与者。第一部分为维生素D磷酸酯透皮贴剂剂量递增,监测安全性和耐受性;第二部分为随机双盲安慰剂对照多臂多阶段试验,比较不同给药频率与安慰剂,主要结局为第4周和第8周血清25(OH)D3浓度较基线的百分比变化。

要点

  • 透皮维生素D磷酸酯贴剂先进行剂量递增,用血清钙和25(OH)D3监测安全性与耐受性。
  • 随机双盲部分先测试不同给药频率4周对比安慰剂,期中分析后选最佳频率再与安慰剂比较。
  • 主要结局为第4周和第8周血清25(OH)D3浓度(ng/mL)较基线的百分比变化。

核心结论

  • 本研究将确定维生素D磷酸酯透皮贴剂能否改善维生素D状态,并可能帮助理解透皮补充后维生素D如何被皮肤直接吸收。

研究设计与样本

  • 单中心、12周、分两部分的研究,最多纳入100名参与者,包含剂量递增阶段和随机双盲安慰剂对照多臂多阶段临床试验。

主要发现

  • 剂量递增研究将通过血清钙和25(OH)D3水平监测安全性和耐受性。
  • 随机双盲试验将比较不同给药频率4周与安慰剂的差异,期中分析后评估最佳给药频率与安慰剂的差异。
  • 主要结局为第4周和第8周血清25(OH)D3浓度(ng/mL)较基线的百分比变化。
  • 次要结局包括第4周和第8周血清维生素D结合蛋白水平、皮肤间质液生物标志物浓度和指甲外观较基线的百分比变化。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lifestyle changes have meant that it is problematic for many people across the globe to maintain adequate vitamin D concentrations. As UV-catalysed production in the skin, which uses vitamin D-binding protein to facilitate systemic absorption, is the primary source of vitamin D, it is questionable if oral supplementation of this vitamin is the optimal means to replace it. However, supplementing an oil-soluble vitamin via the skin is problematic as it gets stuck in the stratum corneum after topical application. This clinical study will test if a new vitamin D ester, vitamin D phosphate, which is more water-soluble compared to vitamin D, administered via a transdermal patch, can be used to improve vitamin D status. METHOD: This is a two-part study comprising a dose-escalation with the vitamin D phosphate transdermal patch followed by a randomised, double-blind, placebo-controlled, multiarmed, multistage clinical trial. It is a single-centred, 12-week study that will enrol a maximum of 100 participants. The dose escalation study will monitor safety and tolerability using serum calcium and 25(OH)D3 levels. The blinded, randomised trial will test different dose frequencies for 4 weeks compared to a placebo. Then, after an interim analysis, the best dosing frequency will be assessed against a placebo. The primary outcome for the multistage clinical study will be the percentage change in 25(OH)D3 concentration in the serum (ng/mL) at weeks 4 and 8 compared to baseline. The secondary outcome measures include percentage change in serum vitamin D-binding protein levels, skin interstitial fluid biomarker concentrations, and nail appearance after 4 and 8 weeks compared to baseline. DISCUSSION: This study will determine if a vitamin D phosphate transdermal patch can improve vitamin D status. In addition, it could provide a better understanding of how vitamin D is absorbed directly into the skin after application by measuring the serum vitamin D-binding protein and skin biomarker responses to transdermal supplementation. TRIAL REGISTRATION: Clinical Trials.gov NCT06098846, registered on 23rd October 2023.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Hibbard T, Andriollo P, Lim CH, et al. A multistage double-blind placebo-controlled study to assess the safety and efficacy of transdermal vitamin D phosphate supplementation (TransVitD). Trials. 2025. PMID: 39972355. doi:10.1186/s13063-024-08711-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。